What's Going On With Eli Lilly Stock On Tuesday?

Zinger Key Points
  • This collaboration supports Lilly's earlier commitment to fighting drug-resistant pathogens through Social Impact Venture Capital Portfolio
  • The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in developing drug-resistant pathogens

On Tuesday, Eli Lilly and Co LLY announced a collaboration with Microsoft Corp MSFT-backed OpenAI that will allow Lilly to leverage OpenAI’s generative AI to invent novel antimicrobials to treat drug-resistant pathogens.

“Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance,” said Diogo Rau, executive vice president and chief information and digital officer at Lilly.

Also Read: Eli Lilly’s Zepbound For Weight Loss Shows Disease Resolution In Obese Sleep Apnea Patients, Lays Further Groundwork For Label Expansion.

“Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens. This partnership underscores our commitment to addressing significant health challenges experienced by people around the world.”

Antimicrobial resistance (AMR) affects countries in all regions and at all income levels and is exacerbated by poverty and inequality, particularly in low- and middle-income countries.

The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in developing drug-resistant pathogens, magnifying this threat to global health.

This collaboration with OpenAI supports Lilly’s earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio.

In 2020, the portfolio committed $100 million to the AMR Action Fund to provide patients with two to four new antibiotics by 2030 and contribute to the next line of defense against multi-drug-resistant pathogens.

In April 2023, the AMR Action Fund announced its latest investments in biotech companies targeting a range of infections. 

In April, Moderna Inc. MRNA announced an ongoing collaboration with OpenAI. Moderna began collaborating with OpenAI in early 2023 with the launch of its own instance of ChatGPT, called mChat. The company announced it has reached more than 80% internal adoption of mChat, accelerating the AI culture at Moderna.

Price Action: LLY shares are up 1.30% at $901.69 at the last check on Tuesday.

Photo via Wikimedia Commons

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareContractsTop StoriesMediaGeneralAIartificial intelligenceBriefsStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!